CA2716950C - Barriers for facilitating biological reactions - Google Patents
Barriers for facilitating biological reactions Download PDFInfo
- Publication number
- CA2716950C CA2716950C CA2716950A CA2716950A CA2716950C CA 2716950 C CA2716950 C CA 2716950C CA 2716950 A CA2716950 A CA 2716950A CA 2716950 A CA2716950 A CA 2716950A CA 2716950 C CA2716950 C CA 2716950C
- Authority
- CA
- Canada
- Prior art keywords
- chamber
- sample
- reagent
- chambers
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000004888 barrier function Effects 0.000 title claims abstract description 31
- 238000006243 chemical reaction Methods 0.000 title abstract description 68
- 238000000034 method Methods 0.000 claims abstract description 147
- 238000000746 purification Methods 0.000 claims abstract description 107
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 56
- 238000004458 analytical method Methods 0.000 claims abstract description 41
- 239000000523 sample Substances 0.000 claims description 176
- 239000003153 chemical reaction reagent Substances 0.000 claims description 83
- 239000007788 liquid Substances 0.000 claims description 64
- 150000007523 nucleic acids Chemical class 0.000 claims description 63
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 58
- 102000039446 nucleic acids Human genes 0.000 claims description 56
- 108020004707 nucleic acids Proteins 0.000 claims description 56
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 56
- 229920001184 polypeptide Polymers 0.000 claims description 54
- 230000005291 magnetic effect Effects 0.000 claims description 52
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 49
- 230000003321 amplification Effects 0.000 claims description 48
- 238000001514 detection method Methods 0.000 claims description 44
- 108090000623 proteins and genes Proteins 0.000 claims description 42
- 239000012530 fluid Substances 0.000 claims description 40
- 239000000126 substance Substances 0.000 claims description 39
- 239000006249 magnetic particle Substances 0.000 claims description 38
- 230000009089 cytolysis Effects 0.000 claims description 36
- 239000000463 material Substances 0.000 claims description 35
- 239000012491 analyte Substances 0.000 claims description 27
- 238000012545 processing Methods 0.000 claims description 26
- 238000010828 elution Methods 0.000 claims description 24
- 102000004169 proteins and genes Human genes 0.000 claims description 24
- 230000033001 locomotion Effects 0.000 claims description 20
- 238000005406 washing Methods 0.000 claims description 18
- 239000007790 solid phase Substances 0.000 claims description 12
- 239000012472 biological sample Substances 0.000 claims description 9
- 230000006037 cell lysis Effects 0.000 claims description 6
- 230000003993 interaction Effects 0.000 claims description 6
- 238000011068 loading method Methods 0.000 claims description 6
- 230000005484 gravity Effects 0.000 claims description 5
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical group FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 claims description 4
- 230000007723 transport mechanism Effects 0.000 claims description 4
- 239000004215 Carbon black (E152) Substances 0.000 claims description 3
- 229930195733 hydrocarbon Natural products 0.000 claims description 3
- 150000002430 hydrocarbons Chemical class 0.000 claims description 3
- 230000005684 electric field Effects 0.000 claims description 2
- 230000002934 lysing effect Effects 0.000 claims description 2
- 239000006226 wash reagent Substances 0.000 claims 1
- 230000008569 process Effects 0.000 abstract description 32
- 230000004048 modification Effects 0.000 abstract description 27
- 238000012986 modification Methods 0.000 abstract description 27
- 230000002209 hydrophobic effect Effects 0.000 abstract description 18
- 238000000926 separation method Methods 0.000 abstract description 13
- 239000002245 particle Substances 0.000 description 168
- 239000001993 wax Substances 0.000 description 101
- 229920002477 rna polymer Polymers 0.000 description 65
- 238000003556 assay Methods 0.000 description 62
- 239000000243 solution Substances 0.000 description 44
- 239000011324 bead Substances 0.000 description 42
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 35
- 239000011534 wash buffer Substances 0.000 description 32
- 239000012149 elution buffer Substances 0.000 description 31
- 239000012139 lysis buffer Substances 0.000 description 31
- 108020004414 DNA Proteins 0.000 description 30
- 102000053602 DNA Human genes 0.000 description 30
- 230000027455 binding Effects 0.000 description 29
- 229960002685 biotin Drugs 0.000 description 27
- 239000011616 biotin Substances 0.000 description 27
- -1 tissues Substances 0.000 description 27
- 239000011888 foil Substances 0.000 description 26
- 239000008206 lipophilic material Substances 0.000 description 26
- 238000003752 polymerase chain reaction Methods 0.000 description 26
- 239000000872 buffer Substances 0.000 description 25
- 238000012360 testing method Methods 0.000 description 25
- 238000002474 experimental method Methods 0.000 description 24
- 210000002381 plasma Anatomy 0.000 description 23
- 239000003921 oil Substances 0.000 description 22
- 235000019198 oils Nutrition 0.000 description 22
- 230000009870 specific binding Effects 0.000 description 22
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 21
- 238000002360 preparation method Methods 0.000 description 21
- 235000018102 proteins Nutrition 0.000 description 21
- 230000032258 transport Effects 0.000 description 21
- 230000003612 virological effect Effects 0.000 description 21
- 235000020958 biotin Nutrition 0.000 description 19
- 239000000203 mixture Substances 0.000 description 19
- 208000006930 Pseudomyxoma Peritonei Diseases 0.000 description 18
- 229920000306 polymethylpentene Polymers 0.000 description 18
- 108091034117 Oligonucleotide Proteins 0.000 description 17
- 235000001014 amino acid Nutrition 0.000 description 17
- 150000001413 amino acids Chemical class 0.000 description 17
- 239000000047 product Substances 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 108010090804 Streptavidin Proteins 0.000 description 15
- 210000002700 urine Anatomy 0.000 description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 14
- 238000009396 hybridization Methods 0.000 description 14
- 235000019441 ethanol Nutrition 0.000 description 13
- 239000003112 inhibitor Substances 0.000 description 13
- 238000011529 RT qPCR Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 239000004033 plastic Substances 0.000 description 12
- 229920003023 plastic Polymers 0.000 description 12
- 241000725303 Human immunodeficiency virus Species 0.000 description 11
- 239000004743 Polypropylene Substances 0.000 description 11
- 108020000999 Viral RNA Proteins 0.000 description 11
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 11
- 239000008188 pellet Substances 0.000 description 11
- 102000040430 polynucleotide Human genes 0.000 description 11
- 108091033319 polynucleotide Proteins 0.000 description 11
- 239000002157 polynucleotide Substances 0.000 description 11
- 229920001155 polypropylene Polymers 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 230000000295 complement effect Effects 0.000 description 10
- 238000002156 mixing Methods 0.000 description 10
- 239000012071 phase Substances 0.000 description 9
- 229920002545 silicone oil Polymers 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 238000003860 storage Methods 0.000 description 9
- 238000012546 transfer Methods 0.000 description 9
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 238000004364 calculation method Methods 0.000 description 8
- 238000002844 melting Methods 0.000 description 8
- 230000008018 melting Effects 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 239000011859 microparticle Substances 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 241000606153 Chlamydia trachomatis Species 0.000 description 7
- 108091026890 Coding region Proteins 0.000 description 7
- 108020004635 Complementary DNA Chemical group 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 229940038705 chlamydia trachomatis Drugs 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 239000011521 glass Substances 0.000 description 7
- 238000003018 immunoassay Methods 0.000 description 7
- 230000000670 limiting effect Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 238000003757 reverse transcription PCR Methods 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 238000010989 Bland-Altman Methods 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 108091092195 Intron Proteins 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 239000007850 fluorescent dye Substances 0.000 description 6
- 238000005755 formation reaction Methods 0.000 description 6
- 230000013595 glycosylation Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 239000002002 slurry Substances 0.000 description 6
- 238000010802 RNA extraction kit Methods 0.000 description 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
- 239000000853 adhesive Substances 0.000 description 5
- 230000001070 adhesive effect Effects 0.000 description 5
- 238000013019 agitation Methods 0.000 description 5
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 5
- 229910052782 aluminium Inorganic materials 0.000 description 5
- 238000010804 cDNA synthesis Methods 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000006073 displacement reaction Methods 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 5
- 229960005191 ferric oxide Drugs 0.000 description 5
- 238000006206 glycosylation reaction Methods 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 5
- 235000013980 iron oxide Nutrition 0.000 description 5
- 238000003754 machining Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 238000011330 nucleic acid test Methods 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 230000004481 post-translational protein modification Effects 0.000 description 5
- 230000001566 pro-viral effect Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 241000606161 Chlamydia Species 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 4
- 239000004809 Teflon Substances 0.000 description 4
- 229920006362 Teflon® Polymers 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000012864 cross contamination Methods 0.000 description 4
- 238000007405 data analysis Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 238000007834 ligase chain reaction Methods 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 238000007899 nucleic acid hybridization Methods 0.000 description 4
- 230000005298 paramagnetic effect Effects 0.000 description 4
- 229920002223 polystyrene Polymers 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 210000002845 virion Anatomy 0.000 description 4
- 239000002699 waste material Substances 0.000 description 4
- BHNQPLPANNDEGL-UHFFFAOYSA-N 2-(4-octylphenoxy)ethanol Chemical compound CCCCCCCCC1=CC=C(OCCO)C=C1 BHNQPLPANNDEGL-UHFFFAOYSA-N 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108090001008 Avidin Chemical group 0.000 description 3
- 102100031780 Endonuclease Human genes 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010018612 Gonorrhoea Diseases 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 108091005461 Nucleic proteins Proteins 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 230000004570 RNA-binding Effects 0.000 description 3
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 235000019519 canola oil Nutrition 0.000 description 3
- 239000000828 canola oil Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 208000001786 gonorrhea Diseases 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- HMFHBZSHGGEWLO-UHFFFAOYSA-N pentofuranose Chemical group OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000005382 thermal cycling Methods 0.000 description 3
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- IQQRAVYLUAZUGX-UHFFFAOYSA-N 1-butyl-3-methylimidazolium Chemical compound CCCCN1C=C[N+](C)=C1 IQQRAVYLUAZUGX-UHFFFAOYSA-N 0.000 description 2
- HPZMWTNATZPBIH-UHFFFAOYSA-N 1-methyladenine Chemical compound CN1C=NC2=NC=NC2=C1N HPZMWTNATZPBIH-UHFFFAOYSA-N 0.000 description 2
- RFLVMTUMFYRZCB-UHFFFAOYSA-N 1-methylguanine Chemical compound O=C1N(C)C(N)=NC2=C1N=CN2 RFLVMTUMFYRZCB-UHFFFAOYSA-N 0.000 description 2
- YSAJFXWTVFGPAX-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetic acid Chemical compound OC(=O)COC1=CNC(=O)NC1=O YSAJFXWTVFGPAX-UHFFFAOYSA-N 0.000 description 2
- FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 2
- OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 2
- OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 description 2
- DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1h-pyrimidine-2-thione Chemical compound NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- 230000005730 ADP ribosylation Effects 0.000 description 2
- 241001504639 Alcedo atthis Species 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- 102100033641 Bromodomain-containing protein 2 Human genes 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108091092584 GDNA Proteins 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 108090001090 Lectins Chemical group 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- HYVABZIGRDEKCD-UHFFFAOYSA-N N(6)-dimethylallyladenine Chemical compound CC(C)=CCNC1=NC=NC2=C1N=CN2 HYVABZIGRDEKCD-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 238000002944 PCR assay Methods 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- 239000007984 Tris EDTA buffer Substances 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 150000001720 carbohydrates Chemical group 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000012875 competitive assay Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000006251 gamma-carboxylation Effects 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 230000033444 hydroxylation Effects 0.000 description 2
- 238000005805 hydroxylation reaction Methods 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 239000002523 lectin Chemical group 0.000 description 2
- 230000005415 magnetization Effects 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000002331 protein detection Methods 0.000 description 2
- 230000009145 protein modification Effects 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 239000012521 purified sample Substances 0.000 description 2
- 238000000275 quality assurance Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 230000019635 sulfation Effects 0.000 description 2
- 238000005670 sulfation reaction Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 238000010798 ubiquitination Methods 0.000 description 2
- 230000034512 ubiquitination Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- ZXMGHDIOOHOAAE-UHFFFAOYSA-N 1,1,1-trifluoro-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)NS(=O)(=O)C(F)(F)F ZXMGHDIOOHOAAE-UHFFFAOYSA-N 0.000 description 1
- QDOIZVITZUBGOQ-UHFFFAOYSA-N 1,1,2,2,3,3,4,4,4-nonafluoro-n,n-bis(1,1,2,2,3,3,4,4,4-nonafluorobutyl)butan-1-amine;1,1,2,2,3,3,4,4,4-nonafluoro-n-(1,1,2,2,3,3,4,4,4-nonafluorobutyl)-n-(trifluoromethyl)butan-1-amine Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)N(C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F.FC(F)(F)C(F)(F)C(F)(F)C(F)(F)N(C(F)(F)C(F)(F)C(F)(F)C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F QDOIZVITZUBGOQ-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- SATCOUWSAZBIJO-UHFFFAOYSA-N 1-methyladenine Natural products N=C1N(C)C=NC2=C1NC=N2 SATCOUWSAZBIJO-UHFFFAOYSA-N 0.000 description 1
- WJNGQIYEQLPJMN-IOSLPCCCSA-N 1-methylinosine Chemical compound C1=NC=2C(=O)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WJNGQIYEQLPJMN-IOSLPCCCSA-N 0.000 description 1
- HLYBTPMYFWWNJN-UHFFFAOYSA-N 2-(2,4-dioxo-1h-pyrimidin-5-yl)-2-hydroxyacetic acid Chemical compound OC(=O)C(O)C1=CNC(=O)NC1=O HLYBTPMYFWWNJN-UHFFFAOYSA-N 0.000 description 1
- SGAKLDIYNFXTCK-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)methylamino]acetic acid Chemical compound OC(=O)CNCC1=CNC(=O)NC1=O SGAKLDIYNFXTCK-UHFFFAOYSA-N 0.000 description 1
- VLEIUWBSEKKKFX-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O VLEIUWBSEKKKFX-UHFFFAOYSA-N 0.000 description 1
- XMSMHKMPBNTBOD-UHFFFAOYSA-N 2-dimethylamino-6-hydroxypurine Chemical compound N1C(N(C)C)=NC(=O)C2=C1N=CN2 XMSMHKMPBNTBOD-UHFFFAOYSA-N 0.000 description 1
- SMADWRYCYBUIKH-UHFFFAOYSA-N 2-methyl-7h-purin-6-amine Chemical compound CC1=NC(N)=C2NC=NC2=N1 SMADWRYCYBUIKH-UHFFFAOYSA-N 0.000 description 1
- KOLPWZCZXAMXKS-UHFFFAOYSA-N 3-methylcytosine Chemical compound CN1C(N)=CC=NC1=O KOLPWZCZXAMXKS-UHFFFAOYSA-N 0.000 description 1
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 1
- GJAKJCICANKRFD-UHFFFAOYSA-N 4-acetyl-4-amino-1,3-dihydropyrimidin-2-one Chemical compound CC(=O)C1(N)NC(=O)NC=C1 GJAKJCICANKRFD-UHFFFAOYSA-N 0.000 description 1
- SJQRQOKXQKVJGJ-UHFFFAOYSA-N 5-(2-aminoethylamino)naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(NCCN)=CC=CC2=C1S(O)(=O)=O SJQRQOKXQKVJGJ-UHFFFAOYSA-N 0.000 description 1
- MQJSSLBGAQJNER-UHFFFAOYSA-N 5-(methylaminomethyl)-1h-pyrimidine-2,4-dione Chemical compound CNCC1=CNC(=O)NC1=O MQJSSLBGAQJNER-UHFFFAOYSA-N 0.000 description 1
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
- KELXHQACBIUYSE-UHFFFAOYSA-N 5-methoxy-1h-pyrimidine-2,4-dione Chemical compound COC1=CNC(=O)NC1=O KELXHQACBIUYSE-UHFFFAOYSA-N 0.000 description 1
- ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- HSPHKCOAUOJLIO-UHFFFAOYSA-N 6-(aziridin-1-ylamino)-1h-pyrimidin-2-one Chemical compound N1C(=O)N=CC=C1NN1CC1 HSPHKCOAUOJLIO-UHFFFAOYSA-N 0.000 description 1
- CKOMXBHMKXXTNW-UHFFFAOYSA-N 6-methyladenine Chemical compound CNC1=NC=NC2=C1N=CN2 CKOMXBHMKXXTNW-UHFFFAOYSA-N 0.000 description 1
- SWJYOKZMYFJUOY-KQYNXXCUSA-N 9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-(methylamino)-7h-purin-8-one Chemical compound OC1=NC=2C(NC)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O SWJYOKZMYFJUOY-KQYNXXCUSA-N 0.000 description 1
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 240000008100 Brassica rapa Species 0.000 description 1
- 230000005653 Brownian motion process Effects 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 244000180278 Copernicia prunifera Species 0.000 description 1
- 235000010919 Copernicia prunifera Nutrition 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BVTJGGGYKAMDBN-UHFFFAOYSA-N Dioxetane Chemical class C1COO1 BVTJGGGYKAMDBN-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000876833 Emberizinae Species 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- KIWBPDUYBMNFTB-UHFFFAOYSA-N Ethyl hydrogen sulfate Chemical compound CCOS(O)(=O)=O KIWBPDUYBMNFTB-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241001553290 Euphorbia antisyphilitica Species 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 239000004831 Hot glue Substances 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- SGSSKEDGVONRGC-UHFFFAOYSA-N N(2)-methylguanine Chemical compound O=C1NC(NC)=NC2=C1N=CN2 SGSSKEDGVONRGC-UHFFFAOYSA-N 0.000 description 1
- PYUSHNKNPOHWEZ-YFKPBYRVSA-N N-formyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC=O PYUSHNKNPOHWEZ-YFKPBYRVSA-N 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108020003217 Nuclear RNA Proteins 0.000 description 1
- 102000043141 Nuclear RNA Human genes 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 108010020713 Tth polymerase Proteins 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000003522 acrylic cement Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000011166 aliquoting Methods 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 238000012197 amplification kit Methods 0.000 description 1
- 239000012164 animal wax Substances 0.000 description 1
- 230000001745 anti-biotin effect Effects 0.000 description 1
- 230000000798 anti-retroviral effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000010516 arginylation Effects 0.000 description 1
- 238000011948 assay development Methods 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 150000001615 biotins Chemical class 0.000 description 1
- HSLXOARVFIWOQF-UHFFFAOYSA-N bis(trifluoromethylsulfonyl)azanide;1-butyl-1-methylpyrrolidin-1-ium Chemical compound CCCC[N+]1(C)CCCC1.FC(F)(F)S(=O)(=O)[N-]S(=O)(=O)C(F)(F)F HSLXOARVFIWOQF-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000005537 brownian motion Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000008364 bulk solution Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-N dCTP Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO[P@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-N 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000005447 environmental material Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 230000001279 glycosylating effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 1
- 150000003278 haem Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000005661 hydrophobic surface Effects 0.000 description 1
- 238000003312 immunocapture Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 239000002608 ionic liquid Substances 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000000990 laser dye Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 229940071125 manganese acetate Drugs 0.000 description 1
- UOGMEBQRZBEZQT-UHFFFAOYSA-L manganese(2+);diacetate Chemical compound [Mn+2].CC([O-])=O.CC([O-])=O UOGMEBQRZBEZQT-UHFFFAOYSA-L 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000005499 meniscus Effects 0.000 description 1
- IZAGSTRIDUNNOY-UHFFFAOYSA-N methyl 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetate Chemical compound COC(=O)COC1=CNC(=O)NC1=O IZAGSTRIDUNNOY-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- ZUZLIXGTXQBUDC-UHFFFAOYSA-N methyltrioctylammonium Chemical compound CCCCCCCC[N+](C)(CCCCCCCC)CCCCCCCC ZUZLIXGTXQBUDC-UHFFFAOYSA-N 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000012184 mineral wax Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- XJVXMWNLQRTRGH-UHFFFAOYSA-N n-(3-methylbut-3-enyl)-2-methylsulfanyl-7h-purin-6-amine Chemical compound CSC1=NC(NCCC(C)=C)=C2NC=NC2=N1 XJVXMWNLQRTRGH-UHFFFAOYSA-N 0.000 description 1
- 150000002790 naphthalenes Chemical class 0.000 description 1
- 229910001172 neodymium magnet Inorganic materials 0.000 description 1
- 108010087904 neutravidin Proteins 0.000 description 1
- 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000007826 nucleic acid assay Methods 0.000 description 1
- 238000001821 nucleic acid purification Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000011101 paper laminate Substances 0.000 description 1
- 235000019809 paraffin wax Nutrition 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- WTWWXOGTJWMJHI-UHFFFAOYSA-N perflubron Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br WTWWXOGTJWMJHI-UHFFFAOYSA-N 0.000 description 1
- 229960001217 perflubron Drugs 0.000 description 1
- 229950011087 perflunafene Drugs 0.000 description 1
- UWEYRJFJVCLAGH-IJWZVTFUSA-N perfluorodecalin Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)[C@@]2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)[C@@]21F UWEYRJFJVCLAGH-IJWZVTFUSA-N 0.000 description 1
- QKENRHXGDUPTEM-UHFFFAOYSA-N perfluorophenanthrene Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)C2(F)C3(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C3(F)C(F)(F)C(F)(F)C21F QKENRHXGDUPTEM-UHFFFAOYSA-N 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000012169 petroleum derived wax Substances 0.000 description 1
- 235000019381 petroleum wax Nutrition 0.000 description 1
- RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000013823 prenylation Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
- 210000005267 prostate cell Anatomy 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 230000003746 surface roughness Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229920001187 thermosetting polymer Polymers 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000007740 vapor deposition Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000012178 vegetable wax Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
- B01L3/502761—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip specially adapted for handling suspended solids or molecules independently from the bulk fluid flow, e.g. for trapping or sorting beads, for physically stretching molecules
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/508—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above
- B01L3/5085—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above for multiple samples, e.g. microtitration plates
- B01L3/50851—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above for multiple samples, e.g. microtitration plates specially adapted for heating or cooling samples
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L7/00—Heating or cooling apparatus; Heat insulating devices
- B01L7/52—Heating or cooling apparatus; Heat insulating devices with provision for submitting samples to a predetermined sequence of different temperatures, e.g. for treating nucleic acid samples
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/04—Exchange or ejection of cartridges, containers or reservoirs
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/06—Fluid handling related problems
- B01L2200/0647—Handling flowable solids, e.g. microscopic beads, cells, particles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/10—Integrating sample preparation and analysis in single entity, e.g. lab-on-a-chip concept
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/16—Reagents, handling or storing thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
- B01L2300/087—Multiple sequential chambers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/04—Moving fluids with specific forces or mechanical means
- B01L2400/0403—Moving fluids with specific forces or mechanical means specific forces
- B01L2400/043—Moving fluids with specific forces or mechanical means specific forces magnetic forces
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/06—Valves, specific forms thereof
- B01L2400/0677—Valves, specific forms thereof phase change valves; Meltable, freezing, dissolvable plugs; Destructible barriers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Clinical Laboratory Science (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Fluid Mechanics (AREA)
- Dispersion Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Sampling And Sample Adjustment (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Physical Or Chemical Processes And Apparatus (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3265508P | 2008-02-29 | 2008-02-29 | |
| US61/032,655 | 2008-02-29 | ||
| PCT/US2009/035497 WO2009111316A2 (en) | 2008-02-29 | 2009-02-27 | Barriers for facilitating biological reactions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2716950A1 CA2716950A1 (en) | 2009-09-11 |
| CA2716950C true CA2716950C (en) | 2017-07-04 |
Family
ID=41056566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2716950A Active CA2716950C (en) | 2008-02-29 | 2009-02-27 | Barriers for facilitating biological reactions |
Country Status (10)
| Country | Link |
|---|---|
| US (6) | US8187808B2 (enExample) |
| EP (1) | EP2257802A4 (enExample) |
| JP (2) | JP5390540B2 (enExample) |
| CN (1) | CN102027367B (enExample) |
| AU (1) | AU2009222181B2 (enExample) |
| BR (1) | BRPI0908876A2 (enExample) |
| CA (1) | CA2716950C (enExample) |
| IL (1) | IL207823A0 (enExample) |
| WO (1) | WO2009111316A2 (enExample) |
| ZA (1) | ZA201006088B (enExample) |
Families Citing this family (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2852148B1 (fr) * | 2003-03-07 | 2014-04-11 | Batscap Sa | Materiau pour electrode composite, procede pour sa preparation |
| CA2592204C (en) * | 2004-12-23 | 2013-03-12 | I-Stat Corporation | Nucleic acid diagnostics system and methods |
| US8841076B2 (en) | 2005-05-09 | 2014-09-23 | Theranos, Inc. | Systems and methods for conducting animal studies |
| US20090047673A1 (en) | 2006-08-22 | 2009-02-19 | Cary Robert B | Miniaturized lateral flow device for rapid and sensitive detection of proteins or nucleic acids |
| EP3756767B1 (en) | 2007-10-02 | 2024-05-01 | Labrador Diagnostics LLC | Modular point-of-care devices and uses thereof |
| EP2257802A4 (en) * | 2008-02-29 | 2014-07-02 | Univ Northwestern | BARRIER FOR BIOLOGICAL REACTIONS |
| WO2009137059A1 (en) | 2008-05-05 | 2009-11-12 | Los Alamos National Security, Llc | Highly simplified lateral flow-based nucleic acid sample preparation and passive fluid flow control |
| RU2529467C2 (ru) | 2009-06-03 | 2014-09-27 | Конинклейке Филипс Электроникс Н.В. | Клапан |
| US9387484B2 (en) * | 2009-10-06 | 2016-07-12 | Koninklijke Philips N.V. | Magnetic sample purification |
| EP2536504A1 (en) * | 2010-02-15 | 2012-12-26 | Danmarks Tekniske Universitet | Sample processing device and method |
| US8728410B2 (en) * | 2010-02-26 | 2014-05-20 | Wisconsin Alumni Research Foundation | Device for and method of extracting a fraction from a biological sample |
| US8603416B2 (en) * | 2010-02-26 | 2013-12-10 | Wisconsin Alumni Research Foundation | Device for and method of extracting a fraction from a biological sample |
| US20130084606A1 (en) * | 2010-06-22 | 2013-04-04 | Universal Bio Research Co., Ltd. | Composition for Preventing Evaporation of Reaction Solution During Nucleic Acid Amplification Reaction |
| US9677979B2 (en) | 2010-07-16 | 2017-06-13 | Vanderbilt University | Low resource processor using surface tension valves for extracting, concentrating and detecting molecular species |
| CN103229053B (zh) | 2010-07-27 | 2015-06-24 | 西北大学 | 过滤血浆的装置和方法 |
| DE102010041621B4 (de) | 2010-09-29 | 2016-11-03 | Hahn-Schickard-Gesellschaft für angewandte Forschung e.V. | Verfahren zum Transport magnetischer Partikel |
| US8993243B2 (en) | 2011-01-10 | 2015-03-31 | Wisconsin Alumni Research Foundation | Method for isolating weakly interacting molecules from a fluidic sample |
| CA3097861A1 (en) | 2011-01-21 | 2012-07-26 | Labrador Diagnostics Llc | Systems and methods for sample use maximization |
| US20120220045A1 (en) * | 2011-02-25 | 2012-08-30 | Colin Bozarth | Double Trench Well for Assay Procedures |
| WO2012121310A1 (ja) | 2011-03-08 | 2012-09-13 | 独立行政法人科学技術振興機構 | ビーズ封入方法、ターゲット分子を検出する方法、アレイ、キット及びターゲット分子検出装置 |
| US10018627B2 (en) * | 2011-03-08 | 2018-07-10 | Japan Science And Technology Agency | Method for sealing substances, method for detecting target molecule, array, kit, and target molecule detection device |
| WO2012133920A1 (ja) * | 2011-03-31 | 2012-10-04 | 国立大学法人九州大学 | 固体色素レーザー媒質およびその製造方法 |
| CA2856304C (en) | 2011-04-20 | 2017-05-16 | Mesa Tech International, Inc. | Oscillating amplification reaction for nucleic acids |
| US20120288866A1 (en) * | 2011-05-11 | 2012-11-15 | Genturadx, Inc. | Systems and methods for producing an evaporation barrier in a reaction chamber |
| US9268915B2 (en) | 2011-09-25 | 2016-02-23 | Theranos, Inc. | Systems and methods for diagnosis or treatment |
| US9664702B2 (en) | 2011-09-25 | 2017-05-30 | Theranos, Inc. | Fluid handling apparatus and configurations |
| US20140170735A1 (en) | 2011-09-25 | 2014-06-19 | Elizabeth A. Holmes | Systems and methods for multi-analysis |
| US8380541B1 (en) | 2011-09-25 | 2013-02-19 | Theranos, Inc. | Systems and methods for collecting and transmitting assay results |
| US8840838B2 (en) | 2011-09-25 | 2014-09-23 | Theranos, Inc. | Centrifuge configurations |
| US9632102B2 (en) | 2011-09-25 | 2017-04-25 | Theranos, Inc. | Systems and methods for multi-purpose analysis |
| US8475739B2 (en) | 2011-09-25 | 2013-07-02 | Theranos, Inc. | Systems and methods for fluid handling |
| US9619627B2 (en) | 2011-09-25 | 2017-04-11 | Theranos, Inc. | Systems and methods for collecting and transmitting assay results |
| US9250229B2 (en) | 2011-09-25 | 2016-02-02 | Theranos, Inc. | Systems and methods for multi-analysis |
| US10012664B2 (en) | 2011-09-25 | 2018-07-03 | Theranos Ip Company, Llc | Systems and methods for fluid and component handling |
| US9810704B2 (en) | 2013-02-18 | 2017-11-07 | Theranos, Inc. | Systems and methods for multi-analysis |
| US20130137108A1 (en) * | 2011-10-25 | 2013-05-30 | Anubhav Tripathi | Magnetic bead separation apparatus and method |
| US20130158240A1 (en) | 2011-12-15 | 2013-06-20 | David Beebe | Method Of Extracting A Fraction From A Biological Sample |
| US20150299766A1 (en) * | 2012-02-23 | 2015-10-22 | Dow Agrosciences Llc | Automation of barrier-based plant nucleic acid and protein extraction |
| GB2561425B (en) | 2012-03-16 | 2019-01-16 | Cambridge Entpr Ltd | Apparatus for obtaining liquid from a solid phase |
| WO2013169730A1 (en) | 2012-05-08 | 2013-11-14 | Quidel Corporation | Device for isolating an analyte from a sample, and methods of use |
| EP2846912A1 (en) | 2012-05-08 | 2015-03-18 | North Western University | Cartridge for use in an automated system for isolating an analyte from a sample, and methods of use |
| WO2014031786A1 (en) * | 2012-08-23 | 2014-02-27 | Northwestern University | Device with controlled fluid dynamics, for isolation of an analyte from a sample |
| US10564077B2 (en) | 2012-09-05 | 2020-02-18 | Wisconsin Alumni Research Foundation | Device for and method of isolating and analyzing a fraction in a biological sample |
| US8728411B2 (en) | 2012-09-05 | 2014-05-20 | Wisconsin Alumni Research Foundation | Device for and method of isolating a fraction in a biological sample |
| US9766166B2 (en) | 2013-01-09 | 2017-09-19 | Wisconsin Alumni Research Foundation | Device and method incorporating a slideable lid for extracting a targeted fraction from a sample |
| JP6120518B2 (ja) * | 2012-10-10 | 2017-04-26 | 公益財団法人かずさＤｎａ研究所 | 簡易測定器具 |
| US9347056B2 (en) | 2012-10-26 | 2016-05-24 | Seiko Epson Corporation | Nucleic acid extraction device, and nucleic acid extraction method, nucleic acid extraction kit, and nucleic acid extraction apparatus, each using the same |
| JP2014093988A (ja) * | 2012-11-12 | 2014-05-22 | Seiko Epson Corp | 固相担体の操作方法及び固相担体の操作装置 |
| WO2014138563A1 (en) | 2013-03-07 | 2014-09-12 | Quidel Corporation | Dual chamber liquid packaging system |
| US9869675B2 (en) | 2013-03-13 | 2018-01-16 | Vanderbilt University | Low resource processor using surface tension valves for extracting, concentrating, and detecting whole cells |
| US11029310B2 (en) | 2013-03-14 | 2021-06-08 | Wisconsin Alumni Research Foundation | Device and method for extracting a targeted fraction from a sample |
| TWI639705B (zh) * | 2016-03-01 | 2018-11-01 | 奎克生技光電股份有限公司 | 多工試片裝置及其操作方法 |
| US11135592B2 (en) * | 2013-06-27 | 2021-10-05 | Quark Biosciences Taiwan, Inc. | Multiplex slide plate device having storage tank |
| US10415084B2 (en) | 2013-06-27 | 2019-09-17 | Quark Biosciences Taiwan, Inc. | Multiplex slide plate device and operation method thereof |
| TWI499779B (zh) * | 2013-07-04 | 2015-09-11 | Ind Tech Res Inst | 檢測晶片及其使用方法 |
| US9463461B2 (en) | 2013-10-25 | 2016-10-11 | The Johns Hopkins University | Self-contained cartridge and methods for integrated biochemical assay at the point-of-care |
| CN103808923A (zh) * | 2013-11-25 | 2014-05-21 | 珠海迪尔生物工程有限公司 | 一种可移动式磁分离荧光免疫检测分析方法及装置 |
| JP2015104363A (ja) * | 2013-11-29 | 2015-06-08 | セイコーエプソン株式会社 | 核酸増幅反応用カートリッジ、及び核酸増幅反応用カートリッジキット |
| JP2015104364A (ja) * | 2013-11-29 | 2015-06-08 | セイコーエプソン株式会社 | 核酸増幅反応用容器、核酸増幅反応用カートリッジ、及び核酸増幅反応用カートリッジキット |
| WO2015086652A1 (en) | 2013-12-12 | 2015-06-18 | Altra Tech Limited | A sample preparation method and apparatus |
| EP3080294B1 (en) | 2013-12-12 | 2018-06-13 | Altratech Limited | A capacitive sensor and method of use |
| US10040062B2 (en) | 2014-01-14 | 2018-08-07 | Wisconsin Alumni Research Foundation | Device and method for transferring a target between locations |
| US10195609B2 (en) * | 2016-10-25 | 2019-02-05 | Fannin Partners, LLC | Assay wells with hydrogel as a well-contents separator and a pigment-based temperature indicator |
| CA2937975A1 (en) | 2014-01-27 | 2015-07-30 | Brevitest Technologies, Llc | Discontinuous fluidic systems for point-of-care analyte measurement |
| US10828636B2 (en) | 2016-10-25 | 2020-11-10 | Fannin Partners Llc | Automated remotely instructed driving of an assay |
| FR3017793B1 (fr) * | 2014-02-21 | 2019-08-23 | Imv Technologies | Paillette pour la conservation d'une dose predeterminee de substance a base liquide, notamment une substance biologique |
| FR3017792B1 (fr) * | 2014-02-21 | 2019-08-23 | Imv Technologies | Paillette pour la conservation d'une dose predeterminee de substance a base liquide, notamment une substance biologique |
| EP3161485B1 (en) | 2014-06-25 | 2018-10-31 | Koninklijke Philips N.V. | Biosensor for the detection of target components in a sample |
| WO2016001963A1 (ja) * | 2014-06-30 | 2016-01-07 | 株式会社日立製作所 | 核酸解析用アレイデバイス、核酸解析装置及び核酸解析方法 |
| AU2015286488B2 (en) | 2014-07-08 | 2020-07-16 | Japan Science And Technology Agency | Substance sealing method and target molecule detecting method |
| JP2016067275A (ja) * | 2014-09-30 | 2016-05-09 | セイコーエプソン株式会社 | 核酸精製デバイス |
| JP2016093157A (ja) * | 2014-11-17 | 2016-05-26 | セイコーエプソン株式会社 | 容器収納体 |
| JP2016093158A (ja) * | 2014-11-17 | 2016-05-26 | セイコーエプソン株式会社 | 容器収納体 |
| JP2016093156A (ja) * | 2014-11-17 | 2016-05-26 | セイコーエプソン株式会社 | 容器収納体 |
| US10616219B2 (en) * | 2014-12-11 | 2020-04-07 | FlowJo, LLC | Single cell data management and analysis systems and methods |
| CN104714026B (zh) * | 2014-12-31 | 2018-08-21 | 北京热景生物技术股份有限公司 | 一种甲胎蛋白异质体的分离检测组合物、系统及其应用 |
| JP6830443B2 (ja) | 2015-04-24 | 2021-02-17 | メサ バイオテック，インク． | 流体検査用カセット |
| WO2016184924A1 (en) * | 2015-05-19 | 2016-11-24 | Bio-Rad Innovations | Use of a low-density immiscible compound in a device for detecting an analyte in a sample |
| JP6651794B2 (ja) * | 2015-11-05 | 2020-02-19 | 富士レビオ株式会社 | 心筋トロポニンｉ測定試薬及び方法 |
| JP2017127224A (ja) * | 2016-01-19 | 2017-07-27 | 株式会社島津製作所 | 核酸前処理キット、および塩基配列解析方法 |
| DE102016209904A1 (de) * | 2016-06-06 | 2017-12-07 | Robert Bosch Gmbh | Verfahren und mikrofluidische Vorrichtung zum Verarbeiten einer Probe biologischen Materials |
| US11249075B2 (en) * | 2016-06-20 | 2022-02-15 | Beckman Coulter, Inc. | Dry-down processes for dye-conjugated reagents |
| US10590409B2 (en) * | 2016-12-06 | 2020-03-17 | Wisconsin Alumni Research Foundation | Method and device for disaggregation via heterogeneous particles |
| ES2928184T3 (es) * | 2016-12-12 | 2022-11-16 | Cepheid | Inmuno-PCR integrado y análisis de ácidos nucleicos en un cartucho de reacción automatizado |
| US12300357B2 (en) | 2016-12-14 | 2025-05-13 | FlowJo, LLC | Applied computer technology for management, synthesis, visualization, and exploration of parameters in large multi-parameter data sets |
| US11573182B2 (en) | 2017-05-25 | 2023-02-07 | FlowJo, LLC | Visualization, comparative analysis, and automated difference detection for large multi-parameter data sets |
| WO2018226891A1 (en) | 2017-06-06 | 2018-12-13 | Northwestern University | Trans-interfacial magnetic separation |
| WO2018234115A1 (en) | 2017-06-19 | 2018-12-27 | Lab-On-A-Bead Ab | Combinatory separation |
| EP3460077B1 (en) * | 2017-09-20 | 2020-06-17 | Altratech Limited | Diagnostic device and system |
| WO2019057515A1 (en) | 2017-09-20 | 2019-03-28 | Altratech Limited | DIAGNOSTIC SYSTEM AND DEVICE |
| CN107748160B (zh) * | 2017-09-21 | 2020-06-02 | 中山大学 | 一种poct即用型微流控芯片及应用方法 |
| CN107561262A (zh) * | 2017-09-30 | 2018-01-09 | 郑州安图生物工程股份有限公司 | 一体化生物及化学反应装置 |
| US20200292565A1 (en) * | 2017-10-11 | 2020-09-17 | Shanghai Rendu Biotechnology Co., Ltd. | Automated nucleic acid sample preparation, detection, and analysis system |
| CN108796038B (zh) * | 2018-06-26 | 2019-10-18 | 杭州优思达生物技术有限公司 | 一种核酸一体化检测方法及检测试剂管 |
| CN114258321B (zh) * | 2019-03-12 | 2023-09-15 | 诺维卢克斯有限责任公司 | 即时浓度分析仪 |
| EP4031647A4 (en) * | 2019-09-20 | 2023-03-01 | Siemens Healthcare Diagnostics, Inc. | IMPROVED ROTOR MIXER FOR STIRRING FLUIDS DURING SAMPLE PREPARATION |
| EP4118204B1 (en) * | 2020-03-13 | 2024-11-13 | Siemens Healthcare Diagnostics, Inc. | A sample lysis and nucleic acid extraction apparatus |
| US20230201833A1 (en) * | 2020-05-28 | 2023-06-29 | The Johns Hopkins University | Magnetofluidic cartridges, devices and related methods of sample analysis |
| US12269031B2 (en) | 2020-06-05 | 2025-04-08 | Wisconsin Alumni Research Foundation | Device and method for accelerated material extraction and detection |
| BR112023015291A2 (pt) | 2021-01-29 | 2023-11-07 | Abbott Diagnostics Scarborough Inc | Transferência de ar por partículas magnéticas |
| EP4334469A4 (en) * | 2021-05-06 | 2025-01-29 | Abbott Molecular Inc. | COMPOSITIONS AND METHODS OF COLLECTION OF SINGLE SAMPLES |
| GB2618578A (en) * | 2022-05-11 | 2023-11-15 | Stratec Se | Method and consumable for nucleic acid extraction |
| DE102022111890B3 (de) | 2022-05-12 | 2023-03-16 | Dermagnostix GmbH | Verfahren zur Deparaffinierung von Formalin-fixiertem Paraffin-eingebettetem Gewebe |
| JP7784545B2 (ja) * | 2022-06-14 | 2025-12-11 | 株式会社日立ハイテク | 核酸溶離液及び当該核酸溶離液を用いた核酸の溶離方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4921612A (en) * | 1985-10-22 | 1990-05-01 | The Trustees Of Stevens Institute Of Technology | Asymmetrically-wettable porous membrane process |
| ATE91023T1 (de) * | 1987-12-01 | 1993-07-15 | Biotope Inc | Verfahren und vorrichtungen zur durchfuehrung von untersuchungen. |
| US5200051A (en) * | 1988-11-14 | 1993-04-06 | I-Stat Corporation | Wholly microfabricated biosensors and process for the manufacture and use thereof |
| US5279936A (en) * | 1989-12-22 | 1994-01-18 | Syntex (U.S.A.) Inc. | Method of separation employing magnetic particles and second medium |
| AU675054B2 (en) * | 1991-11-22 | 1997-01-23 | Affymetrix, Inc. | Combinatorial strategies for polymer synthesis |
| KR100463475B1 (ko) * | 1995-06-08 | 2005-06-22 | 로셰 디아그노스틱스 게엠베하 | 자기성피그먼트 |
| US5856174A (en) * | 1995-06-29 | 1999-01-05 | Affymetrix, Inc. | Integrated nucleic acid diagnostic device |
| US20020022261A1 (en) * | 1995-06-29 | 2002-02-21 | Anderson Rolfe C. | Miniaturized genetic analysis systems and methods |
| US5912129A (en) * | 1998-03-05 | 1999-06-15 | Vinayagamoorthy; Thuraiayah | Multi-zone polymerase/ligase chain reaction |
| US6328782B1 (en) * | 2000-02-04 | 2001-12-11 | Commodore Separation Technologies, Inc. | Combined supported liquid membrane/strip dispersion process for the removal and recovery of radionuclides and metals |
| TW517154B (en) * | 1999-08-11 | 2003-01-11 | Asahi Chemical Ind | Analyzing cartridge and liquid feed control device |
| US20020151040A1 (en) * | 2000-02-18 | 2002-10-17 | Matthew O' Keefe | Apparatus and methods for parallel processing of microvolume liquid reactions |
| US6610499B1 (en) * | 2000-08-31 | 2003-08-26 | The Regents Of The University Of California | Capillary array and related methods |
| FI120863B (fi) * | 2002-10-18 | 2010-04-15 | Biocontrol Systems Inc | Magneettinen siirtomenetelmä ja mikropartikkelien siirtolaite |
| US20060094108A1 (en) * | 2002-12-20 | 2006-05-04 | Karl Yoder | Thermal cycler for microfluidic array assays |
| EP1603674B1 (en) * | 2003-02-05 | 2016-01-06 | Iquum, Inc. | Sample processing |
| FR2858688A1 (fr) * | 2003-08-04 | 2005-02-11 | Gilbert Skorski | Methode et dispositif pour mesurer plusieurs parametres biochimiques dans un echantillon |
| WO2005069015A1 (ja) | 2004-01-15 | 2005-07-28 | Japan Science And Technology Agency | 化学分析装置及び化学分析方法 |
| US7445939B2 (en) * | 2004-02-27 | 2008-11-04 | Varian, Inc. | Stable liquid membranes for liquid phase microextraction |
| US7867443B2 (en) * | 2004-07-23 | 2011-01-11 | Dako Denmark A/S | Method and apparatus for automated pre-treatment and processing of biological samples |
| CA2592204C (en) * | 2004-12-23 | 2013-03-12 | I-Stat Corporation | Nucleic acid diagnostics system and methods |
| EP1890157A4 (en) * | 2005-06-07 | 2011-11-02 | Arkray Inc | LIQUID REPLACEMENT METHOD, COMPONENT EXTRACTING METHOD, COMPOSITE CONTAINER, AND AUTOMATIC ANALYZER |
| WO2007022026A2 (en) * | 2005-08-11 | 2007-02-22 | Biotrove, Inc. | Apparatus for assay, synthesis and storage, and methods of manufacture, use, and manipulation thereof |
| AU2006299414A1 (en) * | 2005-09-30 | 2007-04-12 | Caliper Life Sciences, Inc. | Microfluidic device for purifying a biological component using magnetic beads |
| WO2007094739A1 (en) * | 2006-02-13 | 2007-08-23 | Agency For Science, Technology And Research | Method of processing a biological and/or chemical sample |
| JP4987885B2 (ja) * | 2006-03-09 | 2012-07-25 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | 小滴中で反応を行うための装置及びその使用方法 |
| ATE490971T1 (de) * | 2006-04-18 | 2010-12-15 | Advanced Liquid Logic Inc | Biochemie auf tröpfchenbasis |
| US7439014B2 (en) * | 2006-04-18 | 2008-10-21 | Advanced Liquid Logic, Inc. | Droplet-based surface modification and washing |
| US7745129B1 (en) * | 2006-07-12 | 2010-06-29 | Kenneth David Schatz | Methods for sequencing of a necleic acid |
| US7820454B2 (en) * | 2006-12-29 | 2010-10-26 | Intel Corporation | Programmable electromagnetic array for molecule transport |
| US8298763B2 (en) * | 2007-03-02 | 2012-10-30 | Lawrence Livermore National Security, Llc | Automated high-throughput flow-through real-time diagnostic system |
| EP2072133A1 (en) * | 2007-12-20 | 2009-06-24 | Koninklijke Philips Electronics N.V. | Multi-compartment device with magnetic particles |
| EP2257802A4 (en) * | 2008-02-29 | 2014-07-02 | Univ Northwestern | BARRIER FOR BIOLOGICAL REACTIONS |
-
2009
- 2009-02-27 EP EP09717034.4A patent/EP2257802A4/en not_active Withdrawn
- 2009-02-27 WO PCT/US2009/035497 patent/WO2009111316A2/en not_active Ceased
- 2009-02-27 BR BRPI0908876A patent/BRPI0908876A2/pt not_active Application Discontinuation
- 2009-02-27 CA CA2716950A patent/CA2716950C/en active Active
- 2009-02-27 US US12/395,020 patent/US8187808B2/en active Active
- 2009-02-27 CN CN200980115366.0A patent/CN102027367B/zh active Active
- 2009-02-27 AU AU2009222181A patent/AU2009222181B2/en not_active Ceased
- 2009-02-27 JP JP2010548909A patent/JP5390540B2/ja not_active Expired - Fee Related
-
2010
- 2010-08-26 ZA ZA2010/06088A patent/ZA201006088B/en unknown
- 2010-08-26 IL IL207823A patent/IL207823A0/en unknown
-
2011
- 2011-06-16 US US13/162,530 patent/US8206918B2/en active Active
- 2011-06-16 US US13/162,524 patent/US8304188B2/en active Active
- 2011-12-30 US US13/341,843 patent/US20120129156A1/en not_active Abandoned
-
2012
- 2012-03-15 US US13/421,742 patent/US20120208987A1/en not_active Abandoned
- 2012-10-04 US US13/645,447 patent/US20130034845A1/en not_active Abandoned
-
2013
- 2013-10-09 JP JP2013212226A patent/JP5866325B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009222181A1 (en) | 2009-09-11 |
| IL207823A0 (en) | 2010-12-30 |
| US8187808B2 (en) | 2012-05-29 |
| CN102027367A (zh) | 2011-04-20 |
| US20120208987A1 (en) | 2012-08-16 |
| WO2009111316A2 (en) | 2009-09-11 |
| US20110269190A1 (en) | 2011-11-03 |
| ZA201006088B (en) | 2011-10-26 |
| US20090246782A1 (en) | 2009-10-01 |
| US20120129156A1 (en) | 2012-05-24 |
| JP5866325B2 (ja) | 2016-02-17 |
| BRPI0908876A2 (pt) | 2018-03-13 |
| HK1152377A1 (zh) | 2012-02-24 |
| JP2014012025A (ja) | 2014-01-23 |
| CN102027367B (zh) | 2016-03-23 |
| EP2257802A4 (en) | 2014-07-02 |
| US20110306109A1 (en) | 2011-12-15 |
| AU2009222181B2 (en) | 2014-12-04 |
| US20130034845A1 (en) | 2013-02-07 |
| WO2009111316A3 (en) | 2009-11-26 |
| JP5390540B2 (ja) | 2014-01-15 |
| EP2257802A2 (en) | 2010-12-08 |
| JP2011516034A (ja) | 2011-05-26 |
| CA2716950A1 (en) | 2009-09-11 |
| US8304188B2 (en) | 2012-11-06 |
| US8206918B2 (en) | 2012-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2716950C (en) | Barriers for facilitating biological reactions | |
| Pearlman et al. | Low-resource nucleic acid extraction method enabled by high-gradient magnetic separation | |
| Juang et al. | Oil immersed lossless total analysis system for integrated RNA extraction and detection of SARS-CoV-2 | |
| EP2864503B1 (en) | Nucleic acid amplification and detection kit | |
| Sur et al. | Immiscible phase nucleic acid purification eliminates PCR inhibitors with a single pass of paramagnetic particles through a hydrophobic liquid | |
| CN110760571B (zh) | 数字化定量的多靶标共同、生物检测 | |
| EP2719449A1 (en) | Molecular diagnostics platform that uses digital microfluidics and multiplexed bead detection | |
| WO2011020011A2 (en) | Droplet actuator and droplet-based techniques | |
| US10590477B2 (en) | Method and apparatus for purifying nucleic acids and performing polymerase chain reaction assays using an immiscible fluid | |
| Weigl et al. | Fully integrated multiplexed lab-on-a-card assay for enteric pathogens | |
| Politza et al. | A portable centrifuge for universal nucleic acid extraction at the point-of-care | |
| HK1152377B (en) | Barriers for facilitating biological reactions | |
| Becker et al. | Microfluidic devices for rapid identification and characterization of pathogens | |
| US20250327061A1 (en) | Systems and methods for isolating a target from a fluid sample | |
| KR102625074B1 (ko) | 마이크로입자 기반 핵산 검출용 키트 및 핵산 증폭산물 검출 방법 | |
| US20220081730A1 (en) | Method, system and apparatus for respiratory testing | |
| Juang et al. | Oil Immersed Lossless Total Analysis System (OIL-TAS): Integrated RNA Extraction and Detection for SARS-CoV-2 Testing | |
| Chen | Study and Applications of Microfluidic Chips and Miniaturized Systems for Nucleic Acids Analysis | |
| Adeyiga | Rapid Concentration of Bacteria Using Microfluidic Magnetic Ratcheting | |
| Kinahan et al. | Microfluidic Cell Enumeration for Biomedical Diagnostics | |
| Simon et al. | Chemical Tests |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20140225 |